Navigation Links
Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
Date:8/25/2008

SAN MATEO, Calif., Aug. 25 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.

The FRANCIS trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It will enroll up to 500 patients that will be treated for a minimum of six months. The study will be conducted at sites in North America and Europe. FRANCIS will provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the trial. In this study, MACE is defined as a composite endpoint consisting of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients will receive therapeutic standard of care in addition to high dose Lipitor(R) (atorvastatin). In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, a clinically meaningful and statistically significant reduction in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.

"We are pleased with the continued progress of our varespladib cardiovascular program targeting secretory phospholipase A2," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The FRANCIS trial was designed with input from global regulatory agencies and industry experts and represents the next key
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Reportlinker.com announces that a ... catalogue: mHealth and Home Monitoring – ... Executive summary mHealth can ... better outcomes, decreased costs and improved sustainability of ... is still in an early stage, but on ...
(Date:7/30/2014)... and KISSING, Germany , ... distributor of a single use and computer-assisted ("robotic") colonoscopy ... Shamir , a worldwide recognized medical device executive, as ... Mr. Shamir is a highly respected global visionary ... assignment he served as President and Chief Executive Officer ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Global safety equipment manufacturer MSA (NYSE: MSA ... air-purifying respirator (APR) line in two U.S. factories in ...  The respirators, which include half-mask and full-facepiece models, are ... health officials involved with remediation and containment efforts associated ...
... March 30, 2011 Generex Biotechnology Corporation ( www.generex.com ... a press conference earlier today at the NASDAQ Marketsite ... plan for the Company,s future growth.  A video of ... Generex website. (Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) ...
Cached Medicine Technology:MSA Increases Production of Air-Purifying Respirators to Help Meet Increased Demand from Japan 2Generex Unveils Strategic Development Plan 2Generex Unveils Strategic Development Plan 3Generex Unveils Strategic Development Plan 4Generex Unveils Strategic Development Plan 5Generex Unveils Strategic Development Plan 6Generex Unveils Strategic Development Plan 7Generex Unveils Strategic Development Plan 8Generex Unveils Strategic Development Plan 9
(Date:7/30/2014)... 30, 2014We have pills to ease pain, to cure infection, ... to enhance our sexual and athletic prowess. Why do pills ... we benefit from taking fewer pills? This provocative topic is ... and Fantasy of Pills in Modern Medicine ," published in ... peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article ...
(Date:7/30/2014)... Today, Gen. Arthur T. Dean, Chairman ... (CADCA) , the nation’s leading substance abuse prevention organization, ... New York Times Editorial Board’s call for marijuana ... , “CADCA is disappointed in the New York Times ... marijuana legalization. The move is shortsighted and completely disregards ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Medical costs for chronic obstructive ... than $32 billion each year, according to new research ... The yearly financial toll of COPD (which includes ... estimated $49 billion by 2020. "For the first ... provide state public health practitioners with estimates of the ...
(Date:7/30/2014)... The Europe Phytochemicals & plant extracts market ... market in Europe with analysis and forecast of revenue. ... estimated to grow from around 710.18$ million in 2012 ... 8.4%, for the given period. , Browse through the ... report, to get an idea of the in-depth analysis ...
(Date:7/30/2014)... could help doctors decide which bladder cancer patients would ... according to a study* published in the British ... The University of Manchester, funded by the Medical Research ... levels of a protein, called ,HIF-1α, were more likely ... carbon dioxide gas and nicotinamide tablets at the ...
Breaking Medicine News(10 mins):Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2
... team of researchers at the John Hopkins Hospital in the US ... the PSA to detect prostate cancer.// ,The new test ... a simple blood test. ,Prostate cancer, the most ... of medicine. Physicians are unsure how to find it and when ...
... Thirteen year olds can perform cardiopulmonary resuscitation (CPR) as ... today. The authors suggest that children as young as ... chest compressions. ,Bystander CPR more than doubles ... arrest. Chest compressions are thought to be the most ...
... At least one-third of the time, the symptoms of ... in children, it can be difficult //to distinguish bipolar ... 2007 issue of the Harvard Mental Health Letter. ... the adult cycle of distinct mood episodes of mania ...
... are similar or better than those of whites when differences ... published in the American Heart Journal, Reuters reports. ... Rogers Memorial Veterans Hospital and colleagues studied the care and ... who were treated at five VA hospitals. ...
... Ahmed Obaid, Under-Secretary General and Executive Director of the ... Regional Director of UNFPA have// pressed the need for ... the highest maternal mortality rate in the world. More ... improve the health of the women and children. ...
... of the HIV eradication potential of a bone marrow transplant ... concluded that// eradication is unlikely utilising this method. ... reduce HIV to 'undetectable' levels in the blood, but they ... of our own cells. Although scientists have been working on ...
Cached Medicine News:Health News:New blood test to detect prostate cancer 2Health News:Priority Needs to Be Given to Maternal Health in Afghanistan 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 3
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... multichannel has the same innovative ... model. The same universal handle ... five single channel tip cone ... recharge and storage stand with ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
Medicine Products: